Ticker: UPB

Upstream Bio, Inc. (NASDAQ: UPB) - Q2 2025 Analysis Upstream Bio, Inc. has reported its Q2 2025 financials, revealing a notable expansion in operating expenses amidst continuing development efforts for its clinical-stage product candidate, verekitug. Key Financial Metrics Net Loss: $39.97 millio...

Company OverviewUpstream Bio, Inc. (NASDAQ: UPB) is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory diseases, primarily severe respiratory disorders. They are currently advancing their only product candidate, verekitug, which targets the Thymic Stromal...